Stay updated on Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Sign up to get notified when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.

Latest updates to the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe website footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check25 days agoChange DetectedA site-wide NIH notice was added, announcing updates and FAQs about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference0.5%

- Check32 days agoChange DetectedThe site footer revision changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check39 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check60 days agoChange DetectedIn the record history, the label for finding contact information is capitalized differently ('Find contact information' vs 'Find Contact Information'), and the revision tag updates from v3.6.6 to v3.7.0.SummaryDifference0.1%

- Check82 days agoChange DetectedThe record history now shows a new revision entry v3.6.6, replacing the previous v3.6.5 entry. This updates the study's revision history to reflect a latest change to the record.SummaryDifference0.1%

Stay in the know with updates to Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.